CliffBio
small molecule

ZILRETTA

TRIAMCINOLONE ACETONIDE

Loss of exclusivityAugust 2031latest FDA-listed patent expiry
CompanyPacira Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameZILRETTA
Active ingredientTRIAMCINOLONE ACETONIDE
Strength32MG/VIAL
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteINTRA-ARTICULAR
ModalitySmall molecule
FDA approvalOctober 2017
Marketing statusRX

Listed patents

PatentExpiresType
9555048August 2031use U-2151
8828440August 2031product

More from Pacira Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZILRETTA patent cliff — loss of exclusivity August 2031 | CliffBio